These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 698913)

  • 41. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.
    Palumbo A; Boccadoro M; Bruno B; Triolo S; Pileri A
    Haematologica; 1994; 79(6):513-8. PubMed ID: 7534745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
    Cohen HJ; Silberman HR; Tornyos K; Bartolucci AA
    Blood; 1984 Mar; 63(3):639-48. PubMed ID: 6421344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unmaintained remissions in multiple myeloma.
    Alexanian R; Gehan E; Haut A; Saiki J; Weick J
    Blood; 1978 Jun; 51(6):1005-11. PubMed ID: 647110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The treatment of plasma cell myeloma.
    Bergsagel DE
    Br J Haematol; 1976 Aug; 33(4):443-9. PubMed ID: 795453
    [No Abstract]   [Full Text] [Related]  

  • 48. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
    Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
    Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
    Case DC
    Blood; 1982 May; 59(5):934-7. PubMed ID: 6803856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD
    Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An overview of the status of the nitrosoureas in other tumors.
    Carter SK
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract]   [Full Text] [Related]  

  • 55. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. VBAMDex chemotherapy in advanced multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Glück S; Schumacher K; Deicher H
    Eur J Haematol; 1988 Mar; 40(3):245-9. PubMed ID: 3356240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Durant JR; Loeb V; Dorfman R; Chan YK
    Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.